Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

Novartis

Status: Completed

Conditions: Psoriasis

Treatments: Drug: Secukinumab

Study type: Observational

Funder types: Industry

Identifiers

NCT05320159

CAIN457AUS28

Details and patient eligibility

About

This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.

Full description

This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes. Psoriasis (PsO) patients initiating secukinumab were identified and indexed to the first secukinumab use using the most recent data at study initiation (data period: March 1, 2018 to August 31, 2019) and with a subsequent data refresh (data period: March 1, 2017 - July 31, 2020).

Enrollment: 17,743 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥1 orders/administrations for secukinumab within the index window (March 1, 2018 to August 31,2019 for the base analysis; March 1, 2018 to January 31, 2020 for the refresh analysis). The date of the first order or administration was be the index date
• Patients in the MMDS database with a diagnosis of PsO on or prior to the 1st secukinumab order/administration
• ≥18 years of age as of the index date
• To ensure capturing continuous patient activities in the EMR dataset, patients must have at least one more visit (any visit regardless of diagnosis) in addition to the index visit within the first 6 months after secukinumab initiation
• Patients must have at least one visit (any visit regardless of diagnosis) within the 12 months pre-index period

Exclusion criteria

• Evidence of secukinumab use in the 12-month pre-index period
• Data quality issues (missing age, gender, prescription order information)

Trial design

17,743 participants in 5 patient groups

Overall cohort: Secukinumab

Description:

Included all the patients treated with secukinumab

Treatment:

Drug: Secukinumab

Bio-naive

Description:

Included PsO patients initiating treatment with secukinumab. Bio-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the following biologic drugs of interest anytime pre-index: secukinumab, certolizumab, etanercept, adalimumab, infliximab, golimumab, ustekinumab, ixekizumab, brodalumab, abatacept, and guselkumab and risankizumab during all available history

Treatment:

Drug: Secukinumab

Bio-experienced

Description:

Included PsO patients initiating treatment with secukinumab. Patients had pre-index use of one or more of the biologic drugs of interest during all available history

Treatment:

Drug: Secukinumab

Systemic-naive

Description:

Included PsO patients initiating treatment with secukinumab. Systemic-naïve was defined as no observed treatment (i.e., injection, prescription or patient reported history) with any of the biologic treatments or with any of the following systemic (i.e., oral or injectable - no topical forms) drugs of interest pre-index: methotrexate, corticosteroids, acitretin or apremilast.

Treatment:

Drug: Secukinumab

Systemic-experienced

Description:

Included PsO patients initiating treatment with secukinumab. Systemic-experienced patients had pre-index use of one or more of the systemic drugs of interest.

Treatment:

Drug: Secukinumab